PRP vs Corticosteroids for Tendinopathy: What Does the Evidence Actually Say in 2025?

Platelet-Rich Plasma (PRP) therapy has become one of the most talked-about treatments in musculoskeletal medicine — and for good reason. But with growing enthusiasm comes a responsibility to be honest about what the evidence shows, where it's strong, and where questions remain. At The Re:PAIR Clinic, we only offer treatments grounded in the best available science. So this week, let's look at what 2025's research actually tells us about PRP for tendinopathy.

The Core Finding: PRP Wins at 12 Months — Especially After Conservative Treatment Has Failed

A major 2025 systematic review and meta-analysis published in Pain Medicine examined PRP specifically in patients who had already failed conservative management — physiotherapy, NSAIDs, and rest. The findings were clear: PRP produced a clinically meaningful reduction in pain scores at both 6 and 12 months, with the benefit appearing to grow over time. The largest pain reduction was seen at 12 months. This is a significant finding because it speaks directly to the patient group most of us see in clinic — those who have tried the standard first-line options and are not getting better.

PRP vs Corticosteroids: Short-Term vs Long-Term

One of the most important clinical questions is how PRP compares to corticosteroid injections — still the most commonly offered injectable in NHS and private MSK settings. A 2025 review in Georgetown Medical Review analysed 12 studies and found that 10 of them reported superior long-term outcomes with PRP in at least one major clinical outcome. The picture is nuanced: corticosteroids produce faster pain relief in the short term (within 6 weeks), but are often associated with symptom recurrence and diminishing effect over time. One study even identified imaging evidence of tendon degeneration in the corticosteroid group — a finding consistent with what we know about the catabolic effects of repeated steroid injections on tendon tissue.

In practical terms: if a patient needs fast relief before a significant life event, a corticosteroid may have a role. But for durable, long-term recovery — particularly in lateral epicondylitis and gluteal tendinopathies — PRP shows consistently superior outcomes. Reintervention rates are also lower in PRP-treated patients, which matters both clinically and economically.

The 2-Year RCT Data for Lateral Epicondylosis

A high-quality randomised controlled trial published in The American Journal of Sports Medicine in 2025 followed 202 patients with chronic lateral epicondylosis for 24 months, comparing PRP, prolotherapy, shockwave therapy, and physiotherapy alone. PRP produced the greatest reduction in disability scores — 31 points on the DASH scale compared to 18 points for physiotherapy alone — and the highest patient satisfaction scores at two years. All four treatments exceeded the minimum clinically important difference, but PRP led by a meaningful margin. This is Level 2 evidence from a well-designed trial, and it adds meaningfully to the existing literature.

Where PRP Is More Nuanced: Achilles Tendinopathy

Not every tendon responds equally to PRP, and intellectual honesty requires us to acknowledge this. A 2026 meta-analysis on chronic midportion Achilles tendinopathy found that PRP provides only short-term functional improvement, with no significant long-term structural benefit and no advantage when used as a surgical adjunct. An umbrella review on the same topic drew similar conclusions. The message for Achilles tendinopathy is that evidence-based rehabilitation remains the priority, and PRP should be considered selectively rather than routinely.

Does PRP Formulation Matter? Yes — Significantly

One underappreciated variable in the PRP literature is that 'PRP' is not a single treatment — preparation methods, platelet concentration, leukocyte content, and activation techniques vary enormously between providers. A 2025 meta-analysis in Pain and Therapy found that leukocyte-poor PRP (LP-PRP) was associated with better analgesic outcomes than leukocyte-rich PRP (LR-PRP) for chronic conditions — likely because LR-PRP upregulates pro-inflammatory cytokines that can worsen pain in degenerative tendon disease. By contrast, LR-PRP may be preferable in acute or early-stage injuries where an inflammatory stimulus aids healing.

At The Re:PAIR Clinic, we tailor our PRP preparation to the specific pathology and stage of each patient's condition. This is not a one-size-fits-all treatment — and the evidence confirms that precision in preparation and delivery is what separates good outcomes from inconsistent ones.

The Bottom Line

PRP is not a miracle treatment, and it is not right for every tendon or every patient. But for the right indication — particularly chronic tendinopathy unresponsive to conservative management, lateral epicondylitis, rotator cuff pathology, and gluteal tendinopathy — the 2025 evidence base is meaningful, growing, and increasingly favourable compared to corticosteroids at the 12-month mark and beyond.

If you're living with persistent tendon pain and wondering whether PRP might be appropriate for you, the most important first step is an accurate diagnosis — including ultrasound assessment to characterise the pathology precisely. That's where we start at The Re:PAIR Clinic, every time.

— Dr Chris Ireland, Clinical Director, The Re:PAIR Clinic